Tarsus Pharmaceuticals

-$0.40 (-2.76%) As of 5:02 PM UTC today

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell TARS and other ETFs, options, and stocks.

About TARS

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis.

CEO
Bobak Azamian
Employees
46
Headquarters
Irvine, California
Founded
2017

TARS Key Statistics

Market cap
370.96M
Price-Earnings ratio
—
Dividend yield
—
Average volume
180.08K
High today
$14.70
Low today
$13.97
Open price
$14.44
Volume
54.26K
52 Week high
$39.08
52 Week low
$10.80

TARS Earnings

-$3.71
-$2.32
-$0.92
$0.47
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Estimated
— per share
Actual
Expected Aug 3, After Hours
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure